A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(12 sites)

United States

Research Site, Boston, Massachusetts

Research Site, New York, New York

Research Site, Pittsburgh, Pennsylvania

Research Site, Richmond, Virginia

Japan

Research Site, Chūōku

Research Site, Hidaka-shi

Research Site, Kyoto

United Kingdom

Research Site, Cambridge

Research Site, Glasgow

Research Site, Leeds

Research Site, London